SLRX - Salarius Pharmaceuticals Inc Stock Price, Fair Value and News

0.49USD0.00 (0.00%)Market Closed

Market Summary

USD0.490.00

Market Closed

0.00%

SLRX Stock Price

View Fullscreen

SLRX RSI Chart

SLRX Valuation

Market Cap

2.3M

Price/Earnings (Trailing)

-0.26

Price/Sales (Trailing)

1.22

EV/EBITDA

0.06

Price/Free Cashflow

-0.21

SLRX Price/Sales (Trailing)

SLRX Profitability

EBT Margin

-2025.02%

Return on Equity

-244.34%

Return on Assets

-182.59%

Free Cashflow Yield

-471.3%

SLRX Fundamentals

SLRX Revenue

Revenue (TTM)

1.8M

SLRX Earnings

Earnings (TTM)

-8.9M

Earnings Growth (Yr)

67.88%

Earnings Growth (Qtr)

-94.52%

Breaking Down SLRX Revenue

Last 7 days

-2%

Last 30 days

-3.9%

Last 90 days

-15.5%

Trailing 12 Months

-65.5%

How does SLRX drawdown profile look like?

SLRX Financial Health

Current Ratio

4.66

SLRX Investor Care

Shares Dilution (1Y)

91.71%

Diluted EPS (TTM)

-2.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	5.4M	4.7M	3.3M	1.8M
2020	3.9M	4.3M	4.8M	5.2M
2019	1.5M	2.2M	2.6M	3.5M
2018	1.2M	1.1M	1.2M	1.1M
2017	1.3M	1.5M	1.3M	1.3M
2016	171.8K	268.3K	852.7K	1.1M
2015	22.5K	36.0K	43.8K	72.0K
2014	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Salarius Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 13, 2023	rosenblum mark j	acquired	-	-	6,432	exec vp finance, cfo
Feb 13, 2023	arthur david j.	acquired	-	-	14,300	chief executive officer
Jan 03, 2023	arthur david j.	acquired	-	-	20,000	chief executive officer
Jan 03, 2023	mccreedy bruce j jr.	acquired	-	-	1,440	-
Jan 03, 2023	mcvicar william k.	acquired	-	-	1,440	-
Jan 03, 2023	lammers paul	acquired	-	-	1,440	-
Jan 03, 2023	lieber jonathan i	acquired	-	-	1,440	-
Jan 03, 2023	rosenblum mark j	acquired	-	-	8,000	exec vp finance, cfo
Jan 03, 2023	hanish arnold c	acquired	-	-	1,440	-
Jan 03, 2023	burleson tess	acquired	-	-	1,440	-

Which funds bought or sold SLRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-7.00	32.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-2.00	8.00	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-4.55	-12,798	44,402	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	2.95	-863	4,455	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-8,445	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-15,670	-	-%
May 14, 2024	HORIZON KINETICS ASSET MANAGEMENT LLC	unchanged	-	-3,775	16,436	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-2,760	13,093	-%
May 13, 2024	FMR LLC	reduced	-78.79	-17.00	4.00	-%
May 13, 2024	UBS Group AG	reduced	-76.92	-41.00	10.00	-%

Are Funds Buying or Selling SLRX?

Are funds buying SLRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLRX

No. of Funds

Unveiling Salarius Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	427,350	SC 13G
Oct 27, 2023	lee elvin sanghwan	6.09%	204,270	SC 13D
Feb 13, 2023	lind global fund ii lp	3.8%	89,092	SC 13G/A
Apr 29, 2022	lind global fund ii lp	5.3%	2,969,718	SC 13G
Apr 27, 2022	lincoln park capital fund, llc	5.98%	2,969,718	SC 13G
Feb 16, 2021	cvi investments, inc.	4.1%	804,347	SC 13G/A
Feb 16, 2021	sio capital management, llc	8.35%	1,657,242	SC 13G
Feb 12, 2021	hirschman orin	4.53%	1,130,434	SC 13G/A
Jan 28, 2021	empery asset management, lp	3.90%	804,347	SC 13G/A
Aug 04, 2020	empery asset management, lp	6.90%	1,250,000	SC 13G

Recent SEC filings of Salarius Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
Apr 22, 2024	10-K/A	Annual Report
Apr 12, 2024	4	Insider Trading
Mar 26, 2024	DEF 14A	DEF 14A
Mar 26, 2024	DEFA14A	DEFA14A
Mar 22, 2024	10-K	Annual Report
Mar 20, 2024	DFAN14A	DFAN14A
Mar 15, 2024	PRE 14A	PRE 14A
Mar 06, 2024	8-K	Current Report
Feb 23, 2024	8-K	Current Report

Peers (Alternatives to Salarius Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Salarius Pharmaceuticals Inc News

Latest updates

Salarius Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4
Revenue	-	-	-	571,387	1,268,829	1,478,922	1,378,239	1,243,310	1,132,830	1,038,693	874,949	895,778	655,635	163,067	469,051	245,502	178,582	282,828	413,601	335,523	242,547	298,904
Operating Expenses	10.6%	4,144,856	3,746,660	3,688,207	3,073,424	3,236,250	3,136,744	3,144,264	3,502,388	3,098,719	4,635,114	1,807,880	2,188,419	2,184,206	782,565	9,349,183	-	-	-	-	-	-
S&GA Expenses	-16.3%	1,449,223	1,730,730	1,591,905	1,332,769	1,212,772	1,333,062	1,700,942	1,859,017	1,760,750	3,494,205	967,736	1,488,490	1,921,513	428,958	2,994,649	3,697,287	-	-	-	-	-
R&D Expenses	33.7%	2,695,633	2,015,930	2,096,302	1,740,655	2,023,478	1,803,682	1,443,322	1,643,371	1,337,969	1,140,909	840,144	699,929	187,759	353,607	6,174,589	-	-	-	-	-	-
EBITDA Margin	-80.4%	-20.24	-11.22	-7.93	-6.94	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	294	1,174	2,048	2,340	1,214	3,061	2,138	6,867	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-80.4%	-20.25	-11.23	-7.93	-6.94	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-9.8%	-4,104,873	-3,737,100	-3,074,369	-1,851,896	-1,767,548	-1,716,632	-1,784,258	-2,083,816	-1,882,821	-2,627,721	-903,645	-1,522,076	-2,008,745	-307,450	111,233	-	-	-	-	-	-
Net Income Margin	-120.8%	-6.94	-3.14	-1.79	-1.33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-72.0%	-2,720,603	-1,582,024	-3,174,780	-2,722,790	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-25.9%	4,884	6,587	8,404	12,055	10,055	14,651	19,723	33,654	35,508	40,834	44,263	47,405	50,768	24,932	23,063	18,562	20,065	13,894	14,458	7,137	8,184
Current Assets	-25.9%	4,830	6,520	8,324	11,956	9,940	14,520	17,966	23,015	24,856	30,164	35,184	38,307	41,651	15,797	13,919	9,397	10,884	4,695	5,239	7,109	8,146
Cash Equivalents	-25.9%	4,373	5,900	7,581	11,541	9,274	12,106	16,820	22,647	24,194	29,214	31,904	33,079	36,612	11,119	9,558	7,223	9,647	3,739	4,000	4,138	5,771
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	131	165
Net PPE	-	-	-	-	-	-	-	-	-	4.00	8.00	12.00	15.00	19.00	23.00	16.00	19.00	22.00	25.00	28.00	28.00	38.00
Goodwill	-	-	-	-	-	-	-	-	8,866	8,866	8,866	8,866	8,866	8,866	8,866	8,866	8,866	8,866	8,866	8,866	-	-
Liabilities	-5.0%	1,234	1,299	2,321	3,641	4,496	4,266	3,110	2,770	2,092	2,111	1,612	1,554	1,989	2,773	2,457	1,707	2,063	3,314	4,721	1,036	911
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,036	911
Shareholder's Equity	-31.0%	3,650	5,287	6,084	8,414	5,559	10,385	16,613	30,884	33,416	38,723	42,651	45,851	48,778	22,159	20,606	16,855	18,003	10,581	9,737	733	1,730
Retained Earnings	-2.2%	-78,063	-76,347	-75,466	-73,023	-69,145	-63,805	-57,434	-43,024	-38,306	-32,197	-28,092	-24,355	-21,280	-19,428	-17,661	-15,944	-14,160	-12,076	-10,193	-136,576	-135,191
Additional Paid-In Capital	0.1%	81,712	81,635	81,549	81,437	74,705	74,190	74,047	73,903	71,717	70,920	70,739	70,202	70,054	41,586	38,265	32,798	32,162	22,657	19,927	142,676	142,463
Shares Outstanding	9.5%	4,314	3,938	3,938	3,352	2,468	2,256	2,081	1,996	1,850	1,810	1,792	1,506	1,222	-	-	-	-	-	-	-	-
Float	-	-	-	-	4,921	-	-	-	11,654	-	-	-	47,291	-	-	-	19,158	9,204	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	10.4%	-1,353	-1,511	-3,749	-4,416	-3,169	-4,713	-5,741	-3,619	-3,520	-2,720	-1,582	-3,174	-2,722	-1,373	-2,753	-2,476	-3,708	-2,636	-5,541	-1,533	-1,868
Share Based Compensation	-9.2%	78.00	85.00	113	123	203	146	138	200	314	146	130	147	135	170	78.00	33.00	38.00	172	538	6.00	35.00
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-1,500	-	-	-	-	-2.60	-	-	-	-	5,608	-	-
Cashflow From Financing	-1.9%	-172	-169	-211	6,684	337	1*	-85.69	2,073	-	31.00	406	-358	28,216	2,937	5,088	53.00	9,616	2,376	-204	-99.76	1,508
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34.00	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SLRX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 243,002	$ 3,725,588
General and administrative	1,528,613	1,695,075
Total operating expenses	1,771,615	5,420,663
Loss before other income (expense)	(1,771,615)	(5,420,663)
Interest income, net and other	56,325	79,890
Loss from continuing operations	(1,715,290)	(5,340,773)
Net loss	$ (1,715,290)	$ (5,340,773)
Loss per common share, basic ( in dollar per share)	$ (0.41)	$ (2.23)
Loss per common share, diluted ( in dollar per share)	$ (0.41)	$ (2.23)
Weighted average number of shares outstanding, basic (in shares)	4,194,609	2,391,964
Weighted average number of shares outstanding, diluted (in shares)	4,194,609	2,391,964

SLRX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,373,205	$ 5,899,910
Prepaid expenses and other current assets	457,064	619,763
Total current assets	4,830,269	6,519,673
Other assets	53,390	66,850
Total assets	4,883,659	6,586,523
Current liabilities:
Accounts payable	713,957	602,853
Accrued expenses and other current liabilities	403,309	406,745
Notes payable	116,855	289,643
Total liabilities	1,234,121	1,299,241
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,314,433 and 3,938,433 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	431	393
Additional paid-in capital	81,712,238	81,634,730
Accumulated deficit	(78,063,131)	(76,347,841)
Total stockholders' equity	3,649,538	5,287,282
Total liabilities and stockholders' equity	$ 4,883,659	$ 6,586,523

About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

CEO	Mr. David J. Arthur M.B.A.
WEBSITE	salariuspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Salarius Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Salarius Pharmaceuticals Inc? What does SLRX stand for in stocks?

SLRX is the stock ticker symbol of Salarius Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Salarius Pharmaceuticals Inc (SLRX)?

As of Fri May 17 2024, market cap of Salarius Pharmaceuticals Inc is 2.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLRX stock?

You can check SLRX's fair value in chart for subscribers.

What is the fair value of SLRX stock?

You can check SLRX's fair value in chart for subscribers. The fair value of Salarius Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Salarius Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Salarius Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SLRX is over valued or under valued. Whether Salarius Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Salarius Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLRX.

What is Salarius Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SLRX's PE ratio (Price to Earnings) is -0.26 and Price to Sales (PS) ratio is 1.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLRX PE ratio will change depending on the future growth rate expectations of investors.